Table 1. Summary of outcomes from the 16 prospective controlled trialsa

StudyYearNAC DosingTreatment ArmsPatients (n)Incidence of RCIN
a NAC, N-acetylcysteine; bid, twice daily; tid, thrice daily.
NAC411/41
Tepel (2)2000600 mg bid 1 day before day of study
Placebo429/42
Adamian (47)2002600 mg bidNAC351/35
Control228/22
Allaqaband (10)2002600 mg bid 1 d before and 1 day afterNAC458/45
Control406/40
Briguori (4)2002600 mg bid 1 d before and day of studyNAC926/92
Control9110/92
Diaz-Sandoval (20)2002600 mg bid 1 dose before and 3 d afterNAC252/25
Placebo2913/29
Durham (3)20021200 mg 1 h before and 3 h afterNAC3810/38
Placebo419/41
Goldenberg (48)2003600 mg tid 1 d before and 1 d afterNAC414/41
Placebo393/39
Kahlon (5)2002600 mg bid 1 d before and 1 d afterNAC235/23
Placebo224/22
Oldemeyer (6)20031500 mg bid × 4 dosesNAC494/49
Placebo473/47
Shyu (19)2002400 mg bid 1 d before and day of studyNAC602/60
Placebo6115/61
Vallero (42)2002600 mg bid 1 d before and day of studyNAC122/12
Control80/8
Boccalandro (46)2003600 mg bid day of study and 1 d afterNAC739/73
Control10613/106
Kay (7)2003600 mg bid 1 d before and 1 d afterNAC1024/102
Placebo9812/98
Loutrianakis (49)2003600 mg bid 1 d before and 1 d afterNAC248/24
Placebo233/23
Nogareda (11)2003600 mg × 1 before then bid × 2 dNAC470/47
Control1378/137
Agarwal (unpublished data)800 mg 24 h before then 600 mg bid × 1 dNAC112/11
Placebo142/14